Yuhan Corp - Company Profile
Powered by
All the data and insights you need on Yuhan Corp in one report.
- Save hours of research time and resources with
our up-to-date Yuhan Corp Strategy Report
- Understand Yuhan Corp position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Yuhan Corp Catalyst Calendar
Proactively evaluate Yuhan Corp’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.
A sample of Yuhan Corp Catalyst Calendar data
Event Date | Event Type | Company Name | Ticker Symbol | Drug Name | Therapy Area | Indication | Source Type |
---|---|---|---|---|---|---|---|
01 Nov 2020 | GDCTWXYZ | Lorem | Lorem | Lorem | WXYZ | Planned | Lorem |
09 Mar 2020 | Phase II Trial Initiation | Boryung Pharmaceutical Co Ltd; Dong-A Socio Holdings Co Ltd; Seoul National University Hospital; Yuhan Corp | 000100; 000640; 003850 | gemcitabine hydrochloride; oxaliplatin; pegfilgrastim | Oncology | Peripheral T-Cell Lymphomas (PTCL) | Clinical Trial Registry |
01 Feb 2020 | Phase III Trial Initiation | Korea Drug Development Fund; Parexel International Corp; Yuhan Corp | 000100 | lazertinib | Oncology | Lung Adenocarcinoma; Non-Small Cell Lung Cancer | Clinical Trial Registry |
25 Oct 2019 | Phase II Trial Initiation | Yuhan Corp | 000100 | (amlodipine besylate + telmisartan); rosuvastatin calcium | Cardiovascular; Metabolic Disorders | Hyperlipidemia; Hypertension | GD Estimates |
Feature
Catalyst Calendar provides forecasted drug development milestones within the Pharma industry including expected timing, expected outcomes and possible financial impacts.
Benefit
Access:
- Trial Events for trials conducted globally by a company, university, institute or CRO: Trial Initiation, Trial Completion, Trial Results
- Regulatory Events related to drug filings with regulatory bodies, approvals and commercial launches. This is covered for the US, EU and Japan
- Intellectual Property Events for patent and exclusivity expiry specific to the US, EU and Japan: Constraining Patent Expiry (US/EU/Japan), Drug Expiry (US/EU/Japan), Commercial Launch (US/EU/Japan)
Value
Proactively evaluate companies and catalyst impacts
Stay ahead of the competition & improve corporate planning
Bolster business development with timely opportunities
Premium databases is part of our industry range of products
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer